Modulation of microRNA Expression in Subjects with Metabolic Syndrome and Decrease of Cholesterol Efflux from Macrophages via microRNA-33-Mediated Attenuation of ATP-Binding Cassette Transporter A1 Expression by Statins
Open Access
- 3 May 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5), e0154672
- https://doi.org/10.1371/journal.pone.0154672
Abstract
Metabolic syndrome (MetS) is a complicated health problem that encompasses a variety of metabolic disorders. In this study, we analyzed the relationship between the major biochemical parameters associated with MetS and circulating levels of microRNA (miR)-33, miR-103, and miR-155. We found that miRNA-33 levels were positively correlated with levels of fasting blood glucose, glycosylated hemoglobin A1c, total cholesterol, LDL-cholesterol, and triacylglycerol, but negatively correlated with HDL-cholesterol levels. In the cellular study, miR-33 levels were increased in macrophages treated with high glucose and cholesterol-lowering drugs atorvastatin and pitavastatin. miR-33 has been reported to play an essential role in cholesterol homeostasis through ATP-binding cassette transporter A1 (ABCA1) regulation and reverse cholesterol transport. However, the molecular mechanism underlying the linkage between miR-33 and statin treatment remains unclear. In the present study, we investigated whether atorvastatin and pitavastatin exert their functions through the modulation of miR-33 and ABCA1-mediated cholesterol efflux from macrophages. The results showed that treatment of the statins up-regulated miR-33 expression, but down-regulated ABCA1 mRNA levels in RAW264.7 cells and bone marrow-derived macrophages. Statin-mediated ABCA1 regulation occurs at the post-transcriptional level through targeting of the 3′-UTR of the ABCA1 transcript by miR-33. Additionally, we found significant down-regulation of ABCA1 protein expression in macrophages treated with statins. Finally, we showed that high glucose and statin treatment significantly suppressed cholesterol efflux from macrophages. These findings have highlighted the complexity of statins, which may exert detrimental effects on metabolic abnormalities through regulation of miR-33 target genes.Funding Information
- Ministry of Education, Aim for the Top University Plan (103AC-P504)
- TCVGH-NYMU Joint Research Program (TCVGH-YM1030202)
- Ministry of Science and Technology, Taiwan (MOST 104-3011-B-010-001-1-4-2)
This publication has 54 references indexed in Scilit:
- The microcosmos of cancerNature, 2012
- MicroRNA therapeutics in cardiovascular medicineEMBO Molecular Medicine, 2011
- Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglyceridesNature, 2011
- Macrophages in the Pathogenesis of AtherosclerosisCell, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 ( Srebp2 ) regulates HDL in vivoProceedings of the National Academy of Sciences of the United States of America, 2010
- Hepatic-Specific Disruption of SIRT6 in Mice Results in Fatty Liver Formation Due to Enhanced Glycolysis and Triglyceride SynthesisCell Metabolism, 2010
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- A 52-Week, Randomized, Open-Label, Parallel-Group Comparison of the Tolerability and Effects of Pitavastatin and Atorvastatin on High-Density Lipoprotein Cholesterol Levels and Glucose Metabolism in Japanese Patients with Elevated Levels of Low-Density Lipoprotein Cholesterol and Glucose IntoleranceClinical Therapeutics, 2008
- SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXRBiochemical Journal, 2006